A surge in human metapneumovirus paediatric respiratory admissions in Western Australia following the reduction of SARS-CoV-2 non-pharmaceutical interventions.
SARS-CoV-2
human metapneumovirus
non-pharmaceutical interventions
paediatric
respiratory infection
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
11
05
2023
received:
06
02
2023
accepted:
13
05
2023
medline:
23
10
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
Western Australian laboratory data demonstrated a decrease in human metapneumovirus (hMPV) detections through 2020 associated with SARS-CoV-2-related non-pharmaceutical interventions (NPIs), followed by a subsequent surge in metropolitan region in mid-2021. We aimed to assess the impact of the surge in hMPV on paediatric hospital admissions and the contribution of changes in testing. All respiratory-coded admissions of children aged <16 years at a tertiary paediatric centre between 2017 and 2021 were matched with respiratory virus testing data. Patients were grouped by age at presentation and by ICD-10 AM codes into bronchiolitis, other acute lower respiratory infection (OALRI), wheeze and upper respiratory tract infection (URTI). For analysis, 2017-2019 was utilised as a baseline period. hMPV-positive admissions in 2021 were more than 2.8 times baseline. The largest increase in incidence was observed in the 1-4 years group (incidence rate ratio (IRR) 3.8; 95% confidence interval (CI): 2.5-5.9) and in OALRI clinical phenotype (IRR 2.8; 95% CI: 1.8-4.2). The proportion of respiratory-coded admissions tested for hMPV in 2021 doubled (32-66.2%, P < 0.001), with the greatest increase in wheeze (12-75% in 2021, P < 0.001). hMPV test percentage positivity in 2021 was higher than in the baseline period (7.6% vs. 10.1% in 2021, P = 0.004). The absence and subsequent surge underline the susceptibility of hMPV to NPIs. Increased hMPV-positive admissions in 2021 can be partially attributable to testing, but test-positivity remained high, consistent with a genuine increase. Continued comprehensive testing will help ascertain true burden of hMPV respiratory diseases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
987-991Informations de copyright
© 2023 The Authors. Journal of Paediatrics and Child Health published by John Wiley & Sons Australia, Ltd on behalf of Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Wang X, Li Y, Deloria-Knoll M et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob. Health 2021; 9: e33-43.
Hogan AB, Anderssen RS, Davis S et al. Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western Australia. Epidemics 2016; 16: 49-55.
Yeoh DK, Foley DA, Minney-Smith CA et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin. Infect. Dis. 2021; 72: 2199-202.
Foley DA, Phuong LK, Peplinski J et al. Examining the entire delayed respiratory syncytial virus season in Western Australia. Arch. Dis. Child. 2022; 107: 517-9.
Foley DA, Sikazwe CT, Minney-Smith CA et al. An unusual resurgence of human metapneumovirus in Western Australia following the reduction of non-pharmaceutical interventions to prevent SARS-CoV-2 transmission. Viruses 2022; 14: 2135.
Moore HC, Le H, Mace A et al. Interrupted time-series analysis showed unintended consequences of non-pharmaceutical interventions on pediatric hospital admissions. J. Clin. Epidemiol. 2022; 143: 1-10.
Taylor A, Whittaker E. The changing epidemiology of respiratory viruses in children during the COVID-19 pandemic: A canary in a COVID time. Pediatr. Infect. Dis. J. 2022; 41: e46-8.
Stein M, Cohen H, Nemet I et al. Human metapneumovirus prevalence during 2019-2021 in Israel is influenced by the COVID-19 pandemic. Int. J. Infect. Dis. 2022; 120: 205-9.
Jongbloed M, Leijte WT, Linssen CFM, van den Hoogen BG, van Gorp ECM, de Kruif MD. Clinical impact of human metapneumovirus infections before and during the COVID-19 pandemic. Infect. Dis. 2021; 53: 488-97.
Speers DJ, Moss DM, Minney-Smith C, Levy A, Smith DW. Influenza and respiratory syncytial virus are the major respiratory viruses detected from prospective testing of pediatric and adult coronial autopsies. Influenza Other Respi. Viruses 2013; 7: 1113-21.
Australian Bureau of Statistics. Australian Demographic Statisitics. 2022.
Foley DA, Phuong LK, Peplinski J et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch. Dis. Child. 2022; 107: e7.